Title: Cosmetic or dermatological composition comprising a merocyanine and resveratrol and/or a resveratrol derivative

[0001 ] The present invention relates to a cosmetic or dermatological composition comprising at least one merocyanine of formula (3) which will be defined below in detail and resveratrol and/or at least one resveratrol derivative.

[0002] The present invention also relates to a non-therapeutic cosmetic method for caring for and/or making up a keratin material, comprising the application, to the surface of said keratin material, of at least one composition according to the invention as defined above.

[0003] It also relates to a non-therapeutic cosmetic method for limiting the darkening of the skin and/or improving the colour and/or the uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined above.

[0004] It also relates to a non-therapeutic cosmetic method for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined above.

[0005] It is known that radiation with a wavelength of between 280 nm and 400 nm makes possible tanning of the human epidermis and that radiation with a wavelength of between 280 and 320 nm, known under the name of UVB rays, is harmful to the development of natural tanning. Exposure is also liable to bring about a detrimental change in the biomechanical properties of the epidermis, which is reflected by the appearance of wrinkles, leading to premature ageing of the skin.

[0006] It is also known that UVA rays with a wavelength of between 320 and 400 nm penetrate more deeply into the skin than UVB rays. UVA rays cause immediate and persistent browning of the skin. Daily exposure to UVA rays, even of short duration, under normal conditions can result in damage to the collagen fibres and the elastin, which is reflected by a modification of the microrelief of the skin, the appearance of wrinkles and uneven pigmentation (liver spots, nonuniformity of the complexion).

[0007] Protection against UVA and UVB radiation is thus necessary. An effective photoprotective product must protect against both UVA and UVB radiation.

[0008] Many photoprotective compositions have been proposed to date to overcome the effects induced by UVA and/or UVB radiation. They generally contain organic UV-screening agents and/or inorganic UV- screening agents, which function according to their own chemical nature and according to their own properties by absorption, reflection or scattering of the UV radiation. They generally contain mixtures of fat-soluble organic screening agents and/or of water-soluble UV-screening agents combined with metal oxide pigments, such as titanium dioxide or zinc oxide.

[0009] Many cosmetic compositions intended to limit the darkening of the skin, and to improve the colour and uniformity of the complexion have been proposed to date. It is well known in the field of antisun products that such compositions can be obtained by using UV-screening agents and in particular UVB-screening agents. Some compositions can also contain UVA-screening agents. This screening system must cover UVB protection, for the purpose of limiting and controlling the neosynthesis of melanin promoting overall pigmentation, but must also cover UVA protection, in order to limit and control the oxidation of the pre-existing melanin resulting in the darkening of the colour of the skin.

[0010] However, it is extremely difficult to find a composition containing a particular combination of UV-screening agents which would be especially suitable for the photoprotection of the skin and particularly for an improvement in the quality of the skin both in terms of the colour and in terms of its mechanical elasticity properties.

[0011] Advantageously, this improvement is particularly desired on skin which is already pigmented, for the purpose of not enhancing either the pigmentary melanin load or the structure of the melanin already present within the skin.

[0012] In fact, the majority of organic UV-screening agents consist of aromatic compounds which absorb in the range of wavelengths between 280 and 370 nm. In addition to their ability to screen out solar radiation, the desired photoprotective compounds must also exhibit good cosmetic properties, good solubility in the usual solvents and in particular in fatty substances, such as oils, or in water, and also good photostability, alone or in combination with other UV-screening agents. They must also be colourless or at least exhibit a colour which is cosmetically acceptable to the consumer.

[0013] One of the main disadvantages known to date of these compositions is that these screening systems have insufficient effectiveness against UV radiation and particularly against long UVA radiation with wavelengths above 370 nm with the aim of controlling light- induced pigmentation and its development by a system which screens out UV radiation over the whole of the UV spectrum.

[0014] Among all the compounds which have been recommended for this purpose, an advantageous family of UV-screening agents which is constituted of carbonated merocyanine derivatives has been proposed, which family is described in Patent US 4 195 999, Application WO 2004/006878 and the document IP COM Journal 4 (4), 16 No. IPCOM000011179D, published on 04/03/2004. These compounds exhibit very good screening properties in the long UVA radiation range but exhibit a solubility in the usual solvents, both in the aqueous phase and in the fatty phase, which is only slightly satisfactory and a photostability which is unsatisfactory for some merocyanines.

[0015] With the aim of searching for other merocyanines having a better solubility in the usual solvents and a better photostability, merocyanines comprising polar groups consisting of hydroxyl and ether functional groups which show good screening effectiveness in the long UVA radiation range have been proposed in Application WO 2013/011094. However, the solubility of these particular merocyanines is still not entirely satisfactory and often requires a tedious formulating process. Moreover, the large amounts of solvent necessary in order to dissolve this type of merocyanine can result in cosmetic unpleasantness, such as a tacky and greasy effect on application.

[0016] The need thus remains to improve the solubility of these merocyanines in cosmetic compositions, in particular photoprotective formulations, both in the aqueous phase and in the fatty phase, while obtaining a good cosmetic quality.

[0017] The Applicant Company has discovered, surprisingly, that, by using resveratrol and/or a resveratrol derivative, such as resveratrol triphosphate or polydatin, it is possible to substantially improve the solubility of these merocyanines, both in an aqueous phase and in a fatty phase. This discovery forms the basis of the present invention.

[0018] Thus, in accordance with one of the subject-matters of the present invention, there is now provided a composition, in particular a cosmetic or dermatological composition, comprising at least one merocyanine of formula (3) which will be defined below in detail and resveratrol and/or at least one resveratrol derivative.

[0019] Furthermore, the need also remains to improve the solubility of merocyanines in the presence of organic screening agents. This is because the addition of additional screening agents can destabilize the compositions comprising a merocyanine.

[0020] The Applicant Company has discovered, surprisingly, that, by using resveratrol and/or a resveratrol derivative, it is possible to substantially improve the solubility of these merocyanines in an aqueous phase or in a fatty phase, even in the presence of additional organic UV- screening agents.

[0021 ] The Applicant Company has also discovered that the use of resveratrol or one of its derivatives makes it possible to obtain a good cosmetic quality of the composition comprising the merocyanines, said composition being in particular non-greasy and non-tacky. [0022] The present invention also relates to a non-therapeutic cosmetic method for caring for and/or making up a keratin material, comprising the application, to the surface of said keratin material, of at least one composition according to the invention as defined above.

[0023] It also relates to a non-therapeutic cosmetic method for limiting the darkening of the skin and/or improving the colour and/or the uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined above.

[0024] It also relates to a non-therapeutic cosmetic method for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined above.

[0025] The present invention also relates to the use of resveratrol or one of its derivatives to dissolve a merocyanine of formula (3) as defined below, in particular to dissolve these molecules in the fatty phase and/or in the aqueous phase.

[0026] Other characteristics, aspects and advantages of the invention will become apparent on reading the detailed description which will follow.

[0027] The composition according to the invention is intended for topical application and thus contains a physiologically acceptable medium. The term “physiologically acceptable medium” is understood here to mean a medium which is compatible with keratin materials.

[0028] In the context of the present invention, the term “keratin material” is understood to mean in particular the skin, scalp, keratin fibres, such as the eyelashes, eyebrows, head hair and body hair, nails, mucous membranes, such as the lips, and more particularly the skin and mucous membranes (body, face, area around the eyes, eyelids, lips, preferably body, face and lips).

[0029] In what follows and unless otherwise indicated, the limits of a range of values are included in this range, in particular in the expressions “of between” and “ranging from ... to ...”. [0030] Moreover, the expressions “at least one” and “at least” used in the present description are equivalent respectively to the expressions “one or more” and “greater than or equal to”.

[0031 ] The term "to prevent" or "prevention" is understood to mean, according to the invention, the fact of reducing the risk of onset or of slowing down the onset of a given phenomenon, namely, according to the present invention, the signs of ageing of a keratin material.

MEROCYANINES

[0032] According to the present invention, use will be made of a family of merocyanines corresponding to the following formula (3) and also their geometrical isomer forms, in particular E/E or E/Z geometrical isomer forms:

[Formula 3] in which:

A is -O- or -NH;

R is a C1-C22 alkyl group, a C2-C22 alkenyl group, a C2-C22 alkynyl group, a C3-C22 cycloalkyl group or a C3-C22 cycloalkenyl group, it being possible for said groups to be interrupted by one or more O.

[0033] The merocyanine compounds of the invention can be in their E/E or E/Z geometrical isomer forms:

[Formula 3]

SUBSTITUTE SHEET (RULE 26)

[0034] The compounds of formula (3) which are even more preferential are those where:

A is -O-; R is a C1-C22 alkyl, which can be interrupted by one or more 0. [0035] Use will more particularly be made, among the compounds of formula (3), of those chosen from the following group and also their geometrical isomer forms, in particular E/E or E/Z geometrical isomer forms:

[Table 1]

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26) [0036] According to a more particularly preferred form of the invention, use will be made of the compound 2-ethoxyethyl (2Z)-cyano{3-[(3- methoxypropyl)amino]cyclohex-2-en-1 -ylidene}ethanoate (25) in its E/E and/or E/Z geometrical configuration.

[0037] The E/Z form has the following structure:

[Formula 25]

[0039] The screening merocyanines in accordance with the invention can be present in the compositions according to the invention in a concentration ranging from 0.1 % to 15% by weight, and preferentially from 0.2% to 10% by weight and even better still from 0.5% to 5% by weight, with respect to the total weight of the composition.

[0040] The compounds of formula (3), which form a carbocyclic ring containing 6 carbon atoms, can be prepared according to the protocols described in Pat. Appl. WO 2007/071582, in IP.com Journal (2009), 9(5A), 29-30 IPCOM000182396D under the title “Process for producing 3-amino- 2-cyclohexan-1 -ylidene compounds” and in US-A-4 749 643 on col. 13, line 66 - col. 14, line 57, and the references cited in this regard.

[0041 ] In particular, the compounds of formula (3), such as the compound 2-ethoxyethyl (2Z)-cyano{3-[(3- methoxypropyl)amino]cyclohex-2-en-1 -ylidene}ethanoate (25), can be

SUBSTITUTE SHEET (RULE 26) synthesized according to the synthetic scheme described in the publication by B. Winkler et al., Tetrahedron Letters, 55 (2014), 1749-1751 , which is entitled “A Cyclic Merocyanine IIV-A Absorber: Mechanism of Formation and Crystal Structure”, and represented below, for the compounds of formula (3):

[Formula 4] and more particularly for the compound 25 described in Table 1 :

[Formula 5]

RESVERATROL

[0042] The composition in accordance with the invention comprises resveratrol and/or at least one resveratrol derivative.

[0043] Resveratrol is a polyphenol which exists in a cis form and a trans form, which are represented below:

[Formula 6]

SUBSTITUTE SHEET (RULE 26)

[0044] Resveratrol, in particular trans-resveratrol, is known to have numerous biological properties, such as an anti-oxidizing, antiinflammatory or antitumour activity.

[0045] Resveratrol exists in the natural state in its cis and trans form, but also in other forms, such as, for example, a glucosylated form. It is present in numerous plants and fruits. It is found in particular in Japanese knotweed (Fallopia japonica, also known under the name of Polygonum cupistadum or also Reynoutria japonica) or in grapes, such as, for example, those resulting from the vine species Vitis vinifera. More particularly, resveratrol is found, for example, in blackberries, wine or peanuts.

[0046] Generally, resveratrol is found in the following plant families: Vitaceae, Myrtaceae, Dipterocarpaceae, Cyperaceae, Gnetaceae, Fabaceae, Pinaceae, Polygonaceae, Moraceae, Fagaceae, Liliaceae, and the like.

[0047] Mention may be made, by way of examples of resveratrol derivatives, of resveratrol triphosphate of following formula:

[Formula 7]

[0048] Mention may also be made of polydatin, which is a resveratrol

SUBSTITUTE SHEET (RULE 26) derivative, of following formula:

[Formula 8]

[0049] According to a specific embodiment of the invention, the composition comprises resveratrol. Preferably, the composition comprises resveratrol in its trans form.

[0050] Resveratrol, in particular trans-resveratrol or its derivatives, present in the composition according to the invention, can be of synthetic or natural origin or can be in the form of a plant extract containing resveratrol, in particular trans-resveratrol.

[0051 ] According to a specific embodiment of the invention, said resveratrol and/or resveratrol derivative is present in the composition according to the invention in a content ranging from 0.001 % to 10% by weight, preferably from 0.01 % to 5% by weight, in a preferred way from 0.05% to 2% by weight, with respect to the total weight of the composition.

FATTY PHASE

[0052] The composition in accordance with the invention can comprise at least one fatty phase.

[0053] Within the meaning of the invention, the term "fatty phase" is understood to mean a phase comprising at least one fatty substance, in particular liquid, solid or pasty fatty substance, and all of the fat-soluble and lipophilic ingredients used for the formulation of the compositions of

SUBSTITUTE SHEET (RULE 26) the invention.

[0054] According to a specific embodiment, the composition according to the invention comprises at least one oil.

[0055] The term “oil” is understood to mean any fatty substance in the liquid form at ambient temperature (20-25°C) and at atmospheric pressure (760 mmHg).

[0056] The fatty phase can comprise in particular at least one volatile or non-volatile hydrocarbon oil and/or one volatile and/or non-volatile silicone oil and/or one volatile and/or non-volatile fluorinated oil.

[0057] Within the meaning of the present invention, the term “silicone oil” is understood to mean an oil comprising at least one silicon atom and in particular at least one Si-0 group.

[0058] The term “hydrocarbon oil” is understood to mean an oil mainly containing hydrogen and carbon atoms and optionally one or more heteroatoms, in particular nitrogen and oxygen. Thus, these oils can in particular contain one or more carboxyl, ester, ether or hydroxyl functional groups.

[0059] The term “fluorinated oil” is understood to mean an oil comprising at least one fluorine atom.

[0060] Within the meaning of the invention, the term “volatile oil” is understood to mean an oil which is capable of evaporating on contact with the skin or the keratin fibre in less than one hour, at ambient temperature and atmospheric pressure. The volatile oil(s) of the invention are volatile cosmetic oils, which are liquid at ambient temperature, having a non-zero vapour pressure, at ambient temperature and atmospheric pressure, ranging in particular from 0.13 Pa to 40 000 Pa (10 ^-3 to 300 mmHg), in particular ranging from 1 .3 Pa to 13 000 Pa (0.01 to 100 mmHg) and more particularly ranging from 1 .3 Pa to 1300 Pa (0.01 to 10 mmHg).

[0061] The term “non-volatile oil” is understood to mean an oil which remains on the skin or the keratin fibre at ambient temperature and atmospheric pressure for at least several hours and which has in particular a vapour pressure of less than 10’ ³ mmHg (0.13 Pa).

Hydrocarbon oils

[0062] The composition in accordance with the invention can comprise at least one ester of C2-C22 di- or tricarboxylic acid and of C1-C24 alcohols.

[0063] The C2-C22 di- or tricarboxylic acids are in particular chosen from citric acid, malic acid, malonic acid, succinic acid, adipic acid, maleic acid, fumaric acid, tartaric acid, isocitric acid and their mixtures. Preferably, the acids are citric acid and adipic acid and more preferentially still citric acid is concerned.

[0064] The C1-C24 alcohols are not oxyalkylenated. They can be aliphatic, cyclic or aromatic, having from 1 to 24 carbon atoms. They are chosen in particular from phenol, benzyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, methanol, ethanol, propanol, n- butanol, t-butanol, pentanol or hexanol. Preferably, the alcohol(s) is/are C1- Ce alcohols and can be chosen from methanol, ethanol, propanol, n- butanol, t-butanol, pentanol or hexanol and more preferentially still ethanol is concerned.

[0065] The ester(s) of C2-C22 di- or tricarboxylic acid and of C1-C24 alcohols can be mono- or polyesterified.

[0066] The term “monoesterified” is understood to mean that only one of the two or three carboxylic acid functions is esterified. The term “polyesterified” is understood to mean that at least two carboxylic acid functions are esterified.

[0067] The di- or tricarboxylic acid can be esterified by several different alcohols. Preferably, it is esterified by a single alcohol.

[0068] According to a specific embodiment of the invention, the composition comprises at least one ester of C3-C22 tricarboxylic acid and of C1-C24 , preferably Ci-Ce, alcohols. This or these ester(s) can be mono- , di- or triesterif ied.

[0069] The term “monoesterified” is understood to mean that only one of the three carboxylic acid functions is esterified. The term “diesterified” is understood to mean that two carboxylic acid functions out of the three are esterified. The term “triesterified” is understood to mean that the three carboxylic acid functions are esterified.

[0070] According to a specific embodiment of the invention, the ester(s) of C3-C22 tricarboxylic acid and of Ci-Ce alcohols are triesterified.

[0071 ] According to a specific embodiment of the invention, the ester(s) of C3-C22 tricarboxylic acid and of Ci-Ce alcohols are chosen from the compounds of following formula:

(RI O-CO)CH2-C(R)(OC-OR2)-CH ₂ (OC-OR3) in which:

R1 , R2 and R3 represent, independently of one another, a hydrogen atom or a saturated or unsaturated, aliphatic, cyclic or aromatic, monovalent hydrocarbon group having from 1 to 6 carbon atoms;

R represents a hydrogen atom or a hydroxyl radical.

[0072] According to a preferred embodiment, R1 , R2 and R3 represent, independently of one another, a hydrogen atom or a substituted or unsubstituted, preferably unsubstituted, linear or branched Ci-Ce alkyl radical and in particular a radical chosen from the methyl, ethyl, propyl, n- butyl, t-butyl, pentyl or hexyl radicals. Preferably, R1 , R2 and R3 are chosen, independently of one another, from a hydrogen atom and the methyl, ethyl, propyl, n-butyl or t-butyl radicals.

[0073] According to a preferred embodiment of the invention, the R1, R2 and R3 radicals are identical and are chosen from Ci-Ce, preferably C1- C4, alkyl radicals and more preferentially still are ethyl radicals.

[0074] According to a preferred embodiment of the invention, R represents a hydroxyl radical.

[0075] According to a specific embodiment of the invention, the ester of tricarboxylic acid and of Ci-Ce alcohols exhibits the following formula:

[Formula 9]

[0076] Mention will be made, as example of ester of C3-C22 tricarboxylic acid and of Ci-Ce alcohols of formula (9) and with the INCI name Triethyl Citrate, of that which is sold under the name Citrofol Al Extra by Jungbunzlauer.

[0077] Mention may also be made, as non-volatile hydrocarbon oils which can be used according to the invention, of:

(i) hydrocarbon oils of vegetable origin, such as glyceride triesters, which are generally triesters of fatty acids and of glycerol, the fatty acids of which can have varied chain lengths from C4 to C24, it being possible for these chains to be saturated or unsaturated and linear or branched; these oils are in particular wheat germ oil, sunflower oil, grape seed oil, sesame oil, maize oil, apricot oil, castor oil, shea oil, avocado oil, olive oil, soybean oil, sweet almond oil, palm oil, rapeseed oil, cottonseed oil, hazelnut oil, macadamia oil, jojoba oil, alfalfa oil, poppy oil, red kuri squash oil, pumpkin oil, blackcurrant oil, evening primrose oil, millet oil, barley oil, quinoa oil, rye oil, safflower oil, candlenut oil, passionflower oil or musk rose oil; or alternatively triglycerides of caprylic/capric acids, such as those sold by Stearinerie Dubois or those sold under the names Miglyol 810®, 812® and 818® by Dynamit Nobel;

(ii) synthetic ethers having from 10 to 40 carbon atoms;

(iii) linear or branched hydrocarbons of mineral or synthetic origin, such as liquid petroleum, polydecenes, hydrogenated polyisobutene, such as Parleam, squalane and their mixtures;

(iv) synthetic esters, such as the oils of formula RCOOR' in which R represents the residue of a linear or branched fatty acid comprising from 1 to 40 carbon atoms and R' represents a hydrocarbon chain, in particular branched hydrocarbon chain, containing from 1 to 40 carbon atoms, with the proviso that R + R' > 10, such as, for example, Purcellin oil (cetostearyl octanoate), isopropyl myristate, isopropyl palmitate, C12-C15 alkyl benzoates, such as the product sold under the trade name Finsolv TN® or Witconol TN® by Witco or Tegosoft TN® by Evonik Goldschmidt, 2-ethylphenyl benzoate, such as the commercial product sold under the name X- Tend 226® by ISP, isopropyl lanolate, hexyl laurate, diisopropyl adipate, isononyl isononanoate, oleyl erucate, 2-ethylhexyl palmitate, isostearyl isostearate, diisopropyl sebacate, such as the product sold under the name Dub Dis by Stearinerie Dubois, octanoates, decanoates or ricinoleates of alcohols or of polyalcohols, such as propylene glycol dioctanoate; hydroxylated esters, such as isostearyl lactate or diisostearyl malate; and pentaerythritol esters; citrates or tartrates, such as di(linear C12-C13 alkyl) tartrates, such as those sold under the name Cosmacol ETI® by Enichem Augusta Industriale, and also di(linear C14-C15 alkyl) tartrates, such as those sold under the name Cosmacol ETL® by the same company; acetates;

(v) fatty alcohols which are liquid at ambient temperature, comprising a branched and/or unsaturated carbon-based chain having from 12 to 26 carbon atoms, such as octyldodecanol, isostearyl alcohol, oleyl alcohol, 2-hexyldecanol, 2-butyloctanol or 2-undecylpentadecanol;

(vi) higher C12-C22 fatty acids, such as oleic acid, linoleic acid or linolenic acid;

(vii) carbonates, such as dicaprylyl carbonate, such as the product sold under the name Cetiol CC® by Cognis; and their mixtures.

[0078] Preference will more particularly be given, among the non-volatile hydrocarbon oils which can be used according to the invention, to glyceride triesters and in particular triglycerides of caprylic/capric acids, synthetic esters and in particular diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate, dicaprylyl carbonate, isononyl isononanoate, oleyl erucate, C12- C15 alkyl benzoates or 2-ethylphenyl benzoate, and fatty alcohols, in particular octyldodecanol. Preferably, the non-volatile hydrocarbon oils are chosen from diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate or dicaprylyl carbonate.

[0079] Mention may in particular be made, as volatile hydrocarbon oils which can be used according to the invention, of hydrocarbon oils having from 8 to 16 carbon atoms and in particular of branched Cs-Ci6 alkanes, such as Cs-Ci6 isoalkanes of petroleum origin (also known as isoparaffins), such as isododecane (also known as 2,2,4,4,6-pentamethylheptane), isodecane or isohexadecane, the oils sold under the Isopar or Permethyl trade names, branched Cs-Ci6 esters, isohexyl neopentanoate, and their mixtures.

[0080] Mention may also be made of the alkanes described in the Cognis patent applications WO 2007/068 371 and WO 2008/155 059 (mixtures of distinct alkanes differing by at least one carbon). These alkanes are obtained from fatty alcohols, themselves obtained from coconut or palm oil. Mention may be made of the mixtures of n-undecane (C11) and n- tridecane (C13) obtained in Examples 1 and 2 of Application W02008/155059 of Cognis. Mention may also be made of n-dodecane (C12) and n-tetradecane (C14) sold by Sasol respectively under the references Parafol 12-97 and Parafol 14-97®, and also their mixtures.

[0081] Other volatile hydrocarbon oils, such as petroleum distillates, in particular those sold under the name Shell Solt® by Shell, can also be used. According to one embodiment, the volatile solvent is chosen from volatile hydrocarbon oils having from 8 to 16 carbon atoms, and their mixtures.

Silicone oils

[0082] The non-volatile silicone oils can be chosen in particular from nonvolatile polydimethylsiloxanes (PDMSs), polydimethylsiloxanes comprising alkyl or alkoxy groups, which groups are pendent and/or at the end of the silicone chain and each have from 2 to 24 carbon atoms, or phenylated silicones, such as phenyl trimethicones, phenyl dimethicones, phenyl(trimethylsiloxy)diphenylsiloxanes, diphenyl dimethicones, diphenyl(methyldiphenyl)trisiloxanes or (2- phenylethyl)trimethylsiloxysilicates.

[0083] Mention may be made, as volatile silicone oils, for example, of volatile linear or cyclic silicone oils, in particular those having a viscosity < 8 centistokes (8x1 O’ ⁶ m ² /s) and having in particular from 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups having from 1 to 10 carbon atoms. Mention may in particular be made, as volatile silicone oils which can be used in the invention, of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane and their mixtures.

[0084] A fatty phase according to the invention can additionally comprise other fatty substances, mixed with or dissolved in the oil.

[0085] Another fatty substance which can be present in the fatty phase can, for example, be:

- a fatty acid chosen from fatty acids comprising from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid;

- a wax chosen from waxes such as lanolin, beeswax, carnauba or candelilla wax, rice bran wax, paraffin waxes, lignite waxes, microcrystalline waxes, ceresin or ozokerite, or synthetic waxes, such as polyethylene waxes or Fischer-Tropsch waxes;

- a gum chosen from silicone gums (dimethiconol);

- a pasty compound, such as polymeric or non-polymeric silicone compounds, esters of an oligomeric glycerol, arachidyl propionate, fatty acid triglycerides and their derivatives;

- and their mixtures.

[0086] Preferentially, the overall fatty phase, including all the lipophilic substances other than the lipophilic screening agents of the composition capable of being dissolved in this same phase, represents from 5% to 95% by weight and preferentially from 10% to 80% by weight, with respect to the total weight of the composition.

AQUEOUS PHASE

[0087] The composition in accordance with the invention can comprise at least one aqueous phase.

[0088] The aqueous phase contains water and optionally other water- soluble or water-miscible organic solvents.

[0089] An aqueous phase which is suitable for the invention can comprise, for example, a water chosen from a natural spring water, such as water from La Roche-Posay, water from Vittel, water from Saint-Gervais Mont-Blanc or waters from Vichy, or a floral water.

[0090] According to a specific form of the invention, the overall aqueous phase, including all the hydrophilic substances other than the hydrophilic screening agents of the composition capable of being dissolved in this same phase, represents from 1 % to 99% by weight and preferentially from 10% to 80% by weight, with respect to the total weight of the composition.

ADDITIVES

[0091 ] Additional UV-screeninq agents

[0092] The compositions according to the invention can additionally contain one or more additional UV-screening agents chosen from hydrophilic, lipophilic or insoluble organic UV-screening agents and/or one or more inorganic pigments. It will preferentially be constituted of at least one hydrophilic, lipophilic or insoluble organic UV-screening agent.

[0093] The term "hydrophilic UV-screening agent" is understood to mean any cosmetic or dermatological, organic or inorganic, compound which screens out UV radiation and which is capable of being completely dissolved in the molecular state in a liquid aqueous phase or else of being dissolved in colloidal form (for example in micellar form) in a liquid aqueous phase.

[0094] The term "lipophilic screening agent" is understood to mean any cosmetic or dermatological, organic or inorganic, compound which screens out UV radiation and which is capable of being completely dissolved in the molecular state in a liquid fatty phase or else of being dissolved in colloidal form (for example in micellar form) in a liquid fatty phase. [0095] The term "insoluble UV-screening agent" is understood to mean any cosmetic or dermatological, organic or inorganic, compound which screens out UV radiation and which has a solubility in water of less than 0.5% by weight and a solubility of less than 0.5% by weight in the majority of organic solvents, such as liquid paraffin, fatty alcohol benzoates and fatty acid triglycerides, for example Miglyol 812® sold by Dynamit Nobel. This solubility, determined at 70°C, is defined as the amount of product in solution in the solvent at equilibrium with an excess of solid in suspension after returning to ambient temperature. It can be easily evaluated in the laboratory.

[0096] The additional organic UV-screening agents are chosen in particular from cinnamic compounds; anthranilate compounds; salicylic compounds; dibenzoylmethane compounds; benzylidenecamphor compounds; benzophenone compounds; |3, [3-diphenylacrylate compounds; triazine compounds; benzotriazole compounds; benzalmalonate compounds, in particular those cited in Patent US 5 624 663; benzimidazole derivatives; imidazoline compounds; bis-benzazolyl compounds, such as described in Patents EP 669 323 and US 2 463 264; p-aminobenzoic (PABA) compounds; methylenebis(hydroxyphenylbenzotriazole) compounds, such as described in Applications US 5 237 071 , US 5 166 355, GB 2 303 549, DE 197 26 184 and EP 893 119; benzoxazole compounds, such as described in Patent Applications EP 0 832 642, EP 1 027 883, EP 1 300 137 and DE 101 62 844; screening polymers and screening silicones, such as those described in particular in Application WO 93/04665; dimers derived from a-alkylstyrene, such as those described in Patent Application DE 198 55 649; 4,4-diarylbutadiene compounds, such as described in Applications EP 0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133 980 and EP 133 981 , and their mixtures.

[0097] Mention may be made, as examples of organic photoprotective agents, of those denoted below under their INCI names.

[0098] Cinnamic compounds: Ethylhexyl Methoxycinnamate, sold in particular under the trade name Parsol MCX® by DSM Nutritional Products,

Isopropyl Methoxycinnamate,

Isoamyl p-Methoxycinnamate, sold under the trade name Neo Heliopan E 1000® by Symrise,

DEA Methoxycinnamate,

Diisopropyl Methylcinnamate,

Glyceryl Ethylhexanoate Dimethoxycinnamate.

[0099] Dibenzoylmethane compounds:

Butyl Methoxydibenzoylmethane, sold in particular under the trade name Parsol 1789® by DSM Nutritional Products,

Isopropyl Dibenzoylmethane.

[0100] para-Aminobenzoic compounds:

PABA,

Ethyl PABA,

Ethyl Dihydroxypropyl PABA,

Ethylhexyl Dimethyl PABA, sold in particular under the name Escalol 507® by ISP, Glyceryl PABA,

PEG-25 PABA, sold under the name llvinul P 25® by BASF.

[0101] Salicylic compounds:

Homosalate, sold under the name Eusolex HMS® by Rona/EM Industries, Ethylhexyl Salicylate, sold under the name Neo Heliopan OS® by Symrise, Dipropylene Glycol Salicylate, sold under the name Dipsal® by Scher, TEA Salicylate, sold under the name Neo Heliopan TS® by Symrise.

[0102] 8, ft -Diphenylacrylate compounds:

Octocrylene, sold in particular under the trade name llvinul N 539® by BASF, Etocrylene, sold in particular under the trade name llvinul N 35® by BASF.

[0103] Benzophenone compounds:

Benzophenone-1 , sold under the trade name llvinul 400® by BASF,

Benzophenone-2, sold under the trade name llvinul D 50® by BASF,

Benzophenone-3 or Oxybenzone, sold under the trade name Uvinul M 40® by BASF,

Benzophenone-4, sold under the trade name Uvinul MS 40® by BASF,

Benzophenone-5,

Benzophenone-6, sold under the trade name Helisorb 11® by Norquay,

Benzophenone-8, sold under the trade name Spectra-Sorb UV-24® by American Cyanamid,

Benzophenone-9, sold under the trade name Uvinul DS 49® by BASF,

Benzophenone-12, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate, sold under the trade name Uvinul A Plus® or, as a mixture with octyl methoxycinnamate, under the trade name Uvinul A Plus B® by BASF,

1 , 1 '-(1 ,4-Piperazinediyl)bis[1 -[2-[4-(diethylamino)-2- hydroxybenzoyl]phenyl]methanone] (CAS 919803-06-8), as described in Application W02007/071584; this compound advantageously being used in micronized form (mean size of 0.02 to 2 pm), which can be obtained, for example, according to the micronization process described in Applications GB-A-2 303 549 and EP-A-893 119, and in particular in the form of an aqueous dispersion.

[0104] Benzylidenecamphor compounds:

3-Benzylidene Camphor, manufactured under the name Mexoryl SD® by Chimex,

4-Methylbenzylidene Camphor, sold under the name Eusolex 6300® by Merck, Benzylidene Camphor Sulfonic Acid, manufactured under the name Mexoryl SL® by Chimex,

Camphor Benzalkonium Methosulfate, manufactured under the name Mexoryl SO® by Chimex, Terephthalylidene Dicamphor Sulfonic Acid, manufactured under the name Mexoryl SX® by Chimex,

Polyacrylamidomethyl Benzylidene Camphor, manufactured under the name Mexoryl SW® by Chimex.

[0105] Phenylbenzimidazole compounds:

Phenylbenzimidazole Sulfonic Acid, sold in particular under the trade name Eusolex 232® by Merck.

[0106] Bis-benzazolyl compounds:

Disodium Phenyl Dibenzimidazole Tetrasulfonate, sold under the trade name Neo Heliopan AP® by Haarmann and Reimer.

[0107] Phenylbenzotriazole compounds:

Drometrizole Trisiloxane, sold under the name Silatrizole® by Rhodia Chimie.

[0108] Methylenebis(hvdroxyphenylbenzotriazole) compounds:

Methylene Bis-Benzotriazolyl Tetramethylbutylphenol, in particular in solid form, such as the product sold under the trade name Mixxim BB/100® by Fairmount Chemical, or in the form of an aqueous dispersion of micronized particles having a mean particle size which varies from 0.01 to 5 pm, more preferentially from 0.01 to 2 pm and more particularly from 0.020 to 2 pm, with at least one alkylpolyglycoside surfactant having the structure CnH2n+iO(C6Hio05)xH, in which n is an integer from 8 to 16 and x is the mean degree of polymerization of the (CeH Os) unit and varies from 1 .4 to 1 .6, such as described in Patent GB-A-2 303 549, sold in particular under the trade name Tinosorb M® by BASF, or in the form of an aqueous dispersion of micronized particles having a mean particle size which varies from 0.02 to 2 pm, more preferentially from 0.01 to 1.5 pm and more particularly from 0.02 to 1 pm, in the presence of at least one polyglyceryl mono(C8-C2o)alkyl ester having a degree of glycerol polymerization of at least 5, such as the aqueous dispersions described in Application W02009/063392.

[0109] Triazine compounds:

- 3,3'-(1 ,4-Phenylene)bis(5,6-diphenyl-1 ,2,4-triazine), with the INCI name Phenylene Bis-Diphenyltriazine, and with the following chemical structure: [Formula 10]

- Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, sold under the trade name Tinosorb S® by BASF,

- Ethylhexyl Triazone, sold in particular under the trade name llvinul T 150® by BASF,

- Diethylhexyl Butamido Triazone, sold under the trade name Uvasorb HEB® by Sigma 3V,

- 2,4,6-tris(dineopentyl 4’-aminobenzalmalonate)-s-triazine,

- 2,4,6-tris(diisobutyl 4’-aminobenzalmalonate)-s-triazine,

- 2,4-bis(n-butyl 4’-aminobenzoate)-6-(aminopropyltrisiloxane)-s-triazine,

- 2,4-bis(dineopentyl 4’-aminobenzalmalonate)-6-(n-butyl 4’-aminobenzoate)-s- triazine,

- symmetrical triazine screening agents substituted by naphthalenyl groups or polyphenyl groups described in Patent US 6225467, Application W02004/085412 (see compounds 6 and 9) or the document "Symmetrical Triazine Derivatives", IP.COM IPCOM000031257 Journal, INC West Henrietta, NY, US (20 September 2004), in particular 2,4,6-tris(diphenyl)triazine and 2,4,6-tris(terphenyl)triazine, which is also mentioned in Patent Applications W006/035000, WO06/034982, W006/034991 , W006/035007, W02006/034992 and W02006/034985, these compounds advantageously being used in micronized form (mean particle size of 0.02 to 3 pm), which can be obtained, for example, according to the micronization process described in Applications GB-A-2 303 549 and EP-A-893 119, and in particular in aqueous dispersion form,

SUBSTITUTE SHEET (RULE 26) - silicone triazines substituted by two aminobenzoate groups, such as described in Patent EP 0 841 341 , in particular 2, 4-bis(n-butyl 4’-aminobenzalmalonate)-6-[(3- {1 ,3,3,3-tetramethyl-1 -[(trimethylsilyl)oxy]disiloxanyl}propyl)amino]-s-triazine.

[0110] Anthranilic compounds:

Menthyl Anthranilate, sold under the trade name Neo Heliopan MA® by Symrise.

[0111] Imidazoline compounds:

Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate.

[0112] Benzalmalonate compounds:

Polyorganosiloxane comprising benzalmalonate functional groups, such as Polysilicone-15, sold under the trade name Parsol SLX® by Hoffmann-La Roche.

[0113] 4,4-Diarylbutadiene compounds:

1 , 1 -Dicarboxy(2,2’-dimethylpropyl)-4,4-diphenylbutadiene.

[0114] Benzoxazole compounds:

2,4-Bis[4-[5-(1 ,1 -dimethylpropyl)benzoxazol-2-yl]phenylimino]-6-[(2- ethylhexyl)imino]-1 ,3,5-triazine, sold under the name Uvasorb K2A® by Sigma 3V.

[0115] The preferential organic screening agents are chosen from:

Ethylhexyl Methoxycinnamate,

Ethylhexyl Salicylate,

Homosalate,

Butyl Methoxydibenzoylmethane,

Octocrylene,

Phenylbenzimidazole Sulfonic Acid,

Benzophenone-3,

Benzophenone-4,

Benzophenone-5, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate,

4-Methylbenzylidene Camphor, Terephthalylidene Dicamphor Sulfonic Acid,

Disodium Phenyl Dibenzimidazole Tetrasulfonate,

Methylene Bis-Benzotriazolyl Tetramethylbutylphenol,

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine

Ethylhexyl Triazone,

Diethylhexyl Butamido Triazone,

2.4.6-Tris(dineopentyl 4'-aminobenzalmalonate)-s-triazine,

2.4.6-Tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine,

2.4-Bis(n-butyl 4'-aminobenzoate)-6-(aminopropyltrisiloxane)-s-triazine,

2.4-Bis(dineopentyl 4'-aminobenzalmalonate)-6-(n-butyl 4'-aminobenzoate)-s- triazine,

2.4-Bis(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1 ,3,3,3-tetramethyl-1 -

[(trimethylsilyl)oxy]disiloxanyl}propyl)amino]-s-triazine ,

2.4.6-T ris(diphenyl)triazine,

2,4,6-T ris(terphenyl)triazine,

Drometrizole Trisiloxane,

Polysilicone-15,

1 , 1 -Dicarboxy(2,2'-dimethylpropyl)-4,4-diphenylbutadiene;

2.4-Bis[4-[5-(1 ,1-dimethylpropyl)benzoxazol-2-yl]phenylimino]-6-[(2- ethylhexyl)imino]-1 ,3,5-triazine, and their mixtures.

[0116] The particularly preferred organic screening agents are chosen from:

Ethylhexyl Salicylate,

Homosalate,

Butyl Methoxydibenzoylmethane,

Octocrylene, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate,

Terephthalylidene Dicamphor Sulfonic Acid,

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine,

Ethylhexyl Triazone,

Diethylhexyl Butamido Triazone,

2,4-Bis(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1 ,3,3,3-tetramethyl-1 -

[(trimethylsilyl)oxy]disiloxanyl}propyl)amino]-s-triazine ,

Drometrizole Trisiloxane, and their mixtures.

[0117] The inorganic UV-screening agents used in accordance with the present invention are metal oxide pigments. More preferentially, the inorganic UV-screening agents of the invention are metal oxide particles having a mean elementary particle size of less than or equal to 0.5 pm, more preferentially of between 0.005 and 0.5 pm, more preferentially still of between 0.01 and 0.2 pm, better still between 0.01 and 0.1 pm and more particularly between 0.015 and 0.05 pm.

[0118] They can be chosen in particular from titanium oxide, zinc oxide, iron oxide, zirconium oxide, cerium oxide or their mixtures.

[0119] Such coated or non-coated metal oxide pigments are described in particular in Patent Application EP-A-0 518 773. Mention may be made, as commercial pigments, of the products sold by Sachtleben Pigments, Tayca, Merck and Degussa.

[0120] The metal oxide pigments can be coated or non-coated.

[0121 ] The coated pigments are pigments which have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminium salts of fatty acids, metal alkoxides (of titanium or aluminium), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.

[0122] The coated pigments are more particularly titanium oxides coated:

- with silica, such as the product Sunveil® from Ikeda,

- with silica and iron oxide, such as the product Sunveil F® from Ikeda,

- with silica and alumina, such as the products Microtitanium Dioxide MT 500 SA® and Microtitanium Dioxide MT 100 SA from Tayca and Tioveil from Tioxide,

- with alumina, such as the products Tipaque TTO-55 (B)® and Tipaque TTO-55 (A)® from Ishihara and UVT 14/4 from Sachtleben Pigments,

- with alumina and aluminium stearate, such as the products Microtitanium Dioxide MT 100 T®, MT 100 TX®, MT 100 Z® and MT-01® from Tayca, the products Solaveil CT-10 W® and Solaveil CT 100® from Uniqema and the product Eusolex T-AVO® from Merck,

- with silica, alumina and alginic acid, such as the product MT-100 AQ® from Tayca,

- with alumina and aluminium laurate, such as the product Microtitanium Dioxide MT 100 S® from Tayca,

- with iron oxide and iron stearate, such as the product Microtitanium Dioxide MT 100 F® from Tayca,

- with zinc oxide and zinc stearate, such as the product BR 351® from Tayca,

- with silica and alumina and treated with a silicone, such as the products Microtitanium Dioxide MT 600 SAS®, Microtitanium Dioxide MT 500 SAS® or Microtitanium Dioxide MT 100 SAS® from Tayca,

- with silica, alumina and aluminium stearate and treated with a silicone, such as the product STT-30-DS® from Titan Kogyo,

- with silica and treated with a silicone, such as the product UV-Titan X 195® from Sachtleben Pigments,

- with alumina and treated with a silicone, such as the products Tipaque TTO-55 (S)® from Ishihara or UV Titan M 262® from Sachtleben Pigments,

- with triethanolamine, such as the product STT-65-S from Titan Kogyo, - with stearic acid, such as the product Tipaque TTO-55 (C)® from Ishihara,

- with sodium hexametaphosphate, such as the product Microtitanium Dioxide MT 150 W® from Tayca,

- TiO2 treated with octyltrimethylsilane, sold under the trade name T 805® by Degussa Silices,

- TiO2 treated with a polydimethylsiloxane, sold under the trade name 70250 Cardre UF TiO2SI3® by Cardre,

- anatase/rutile TiO2 treated with a polydimethylhydrosiloxane, sold under the trade name Micro Titanium Dioxide USP Grade Hydrophobic® by Color Techniques,

- TiO2 coated with triethylhexanoin, aluminium stearate and alumina, sold under the trade name Solaveil CT-200-LQ-(WD) by Croda,

- TiO2 coated with aluminium stearate, alumina and silicone, sold under the trade name Solaveil CT-12W-LQ-(WD) by Croda,

- TiO2 coated with lauroyl lysine, sold by Daito Kasei Kogyo under the name LL 5 Titanium Dioxide CR 50,

- TiO2 coated with C9-15 fluoroalcohol phosphate and aluminium hydroxide, sold by Daito Kasei Kogyo under the name PFX-5 TiO2 CR-50.

[0123] Mention may also be made of TiO2 pigments doped with at least one transition metal, such as iron, zinc or manganese and more particularly manganese. Preferably, said doped pigments are in the form of an oily dispersion. The oil present in the oily dispersion is preferably chosen from triglycerides, including those of capric/caprylic acids. The oily dispersion of titanium oxide particles can additionally comprise one or more dispersing agents, such as, for example, a sorbitan ester, such as sorbitan isostearate, a polyoxyalkylenated glycerol fatty acid ester, such as Tri- PPG-3 Myristyl Ether Citrate and Polyglyceryl-3 Polyricinoleate. Preferably, the oily dispersion of titanium oxide particles comprises at least one dispersing agent chosen from polyoxyalkylenated glycerol fatty acid esters. Mention may more particularly be made of the oily dispersion of TiO2 particles doped with manganese in capric/caprylic acid triglyceride in the presence of Tri-PPG-3 Myristyl Ether Citrate and Polyglyceryl-3 Polyricinoleate and Sorbitan Isostearate with the INCI name: Titanium Dioxide (and) Tri-PPG-3 Myristyl Ether Citrate (and) Polyglyceryl-3 Ricinoleate (and) Sorbitan Isostearate, such as the product sold under the trade name Optisol TD50® by Croda.

[0124] The non-coated titanium oxide pigments are sold, for example, by

Tayca under the trade names Microtitanium Dioxide MT 500 B or Microtitanium Dioxide MT 600 B®, by Degussa under the name P 25, by Wacker under the name Transparent Titanium Oxide PW®, by Miyoshi Kasei under the name LIFTR®, by Tomen under the name ITS® and by Tioxide under the name Tioveil AQ.

[0125] The non-coated zinc oxide pigments are, for example:

- those sold under the name Z-Cote by Sunsmart;

- those sold under the name Nanox® by Elementis;

- those sold under the name Nanogard WCD 2025® by Nanophase Technologies.

[0126] The coated zinc oxide pigments are, for example:

- those sold under the name Zinc Oxide CS-5® by Toshibi (ZnO coated with polymethylhydrosiloxane);

- those sold under the name Nanogard Zinc Oxide FN® by Nanophase Technologies (as a 40% dispersion in Finsolv TN®, C12-C15 alkyl benzoates);

- those sold under the name Daitopersion Zn-30® and Daitopersion Zn-50® by Daito (dispersions in oxyethylenated cyclopolymethylsiloxane/polydimethylsiloxane, containing 30% or 50% of zinc oxides coated with silica and polymethylhydrosiloxane);

- those sold under the name NFD Ultrafine ZnO® by Daikin (ZnO coated with perfluoroalkyl phosphate and copolymer based on perfluoroalkylethyl in dispersion in cyclopentasiloxane);

- those sold under the name SPD-Z1® by Shin-Etsu (ZnO coated with silicone- grafted acrylic polymer, dispersed in cyclodimethylsiloxane);

- those sold under the name Escalol Z100® by ISP (alumina-treated ZnO dispersed in the ethylhexyl methoxycinnamate/PVP-hexadecene copolymer/methicone mixture);

- those sold under the name Fuji ZnO-SMS-10® by Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane);

- those sold under the name Nanox Gel TN® by Elementis (ZnO dispersed at 55% in C12-C15 alkyl benzoates with hydroxystearic acid polycondensate).

[0127] The non-coated cerium oxide pigments can, for example, be those sold under the name Colloidal Cerium Oxide® by Rhone-Poulenc.

[0128] The non-coated iron oxide pigments are, for example, sold by Arnaud under the names Nanogard WCD 2002® (FE 45B®), Nanogard Iron FE 45 BL AQ, Nanogard FE 45R AQ® and Nanogard WCD 2006® (FE 45R®) or by Mitsubishi under the name TY-220®.

[0129] The coated iron oxide pigments are, for example, sold by Arnaud under the names Nanogard WCD 2008 (FE 45B FN)®, Nanogard WCD 2009® (FE 45B 556®), Nanogard FE 45 BL 345® and Nanogard FE 45 BL® or by BASF under the name Transparent Iron Oxide.

[0130] Mention may also be made of mixtures of metal oxides, in particular of titanium dioxide and cerium dioxide, including the mixture in equal weights of titanium dioxide and cerium dioxide coated with silica, sold by Ikeda under the name Sunveil A®, and also the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone, such as the product M 261® sold by Sachtleben Pigments, or coated with alumina, silica and glycerol, such as the product M 211® sold by Sachtleben Pigments.

[0131] According to the invention, coated or non-coated titanium oxide pigments are particularly preferred.

[0132] The additional UV-screening agents according to the invention can be present in the composition according to the invention at a content ranging from 0.1 % to 60% by weight and in particular from 5% to 30% by weight, with respect to the total weight of the composition.

Other additives [0133] The composition in accordance with the present invention can additionally comprise conventional cosmetic adjuvants chosen in particular from organic solvents, ionic or non-ionic thickeners, softeners, humectants, opacifiers, stabilizers, emollients, silicones, antifoaming agents, fragrances, preservatives, anionic, cationic, non-ionic, zwitterionic or amphoteric surfactants, active agents, fillers, polymers, propellants, basifying or acidifying agents or any other ingredient generally used in the cosmetic and/or dermatological field.

[0134] Mention may be made, among organic solvents, of short-chain monoalcohols, for example C1-C4 monoalcohols, such as ethanol and isopropanol, short-chain C2-C8 polyols, such as glycerol, diols, such as caprylyl glycol, 1 ,2-pentanediol, propanediol or butanediol, glycols and glycol ethers, such as ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol or diethylene glycol, 2-ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, sorbitol, and their mixtures.

[0135] According to a preferred embodiment, use may more particularly be made of ethanol, propylene glycol, glycerol, and their mixtures.

[0136] Mention may be made, as thickeners, of carboxyvinyl polymers, such as the Carbopols® (Carbomers) and the Pemulens, such as Pemulen TR1® and Pemulen TR2® (Acrylates/C10-C30 Alkyl Acrylate Crosspolymer); polyacrylamides, such as, for example, the crosslinked copolymers sold under the names Sepigel 305® (CTFA name: Polyacrylamide/C13-14 lsoparaffin/Laureth-7) or Simulgel 600 (CTFA name: Acrylamide/Sodium Acryloyldimethyl Taurate

Copolymer/lsohexadecane/Polysorbate 80) by SEPPIC; 2-acrylamido-2- methylpropanesulfonic acid polymers and copolymers which are optionally crosslinked and/or neutralized, such as the poly(2-acrylamido-2- methylpropanesulfonic acid) sold by Hoechst under the trade name Hostacerin AMPS® (CTFA name: Ammonium Polyacryloyldimethyl Taurate) or Simulgel 800® sold by SEPPIC (CTFA name: Sodium Polyacryloyldimethyl Taurate/Polysorbate 80/Sorbitan Oleate); copolymers of 2-acrylamido-2-methylpropanesulfonic acid and of hydroxyethyl acrylate, such as Simulgel NS® and Sepinov EMT 10® sold by SEPPIC; cellulose derivatives, such as hydroxyethylcellulose; polysaccharides and in particular gums, such as xanthan gum; water- soluble or water-dispersible silicone derivatives, such as acrylic silicones, polyether silicones and cationic silicones, and their mixtures.

[0137] Mention may be made, among the acidifying agents, by way of example, of inorganic or organic acids, such as hydrochloric acid, orthophosphoric acid, sulfuric acid, carboxylic acids, such as acetic acid, tartaric acid, citric acid or lactic acid, or sulfonic acids.

[0138] Mention may be made, among the basifying agents, by way of example, of aqueous ammonia, alkali metal carbonates, alkanolamines, such as mono-, di- and triethanolamines and their derivatives, sodium hydroxide or potassium hydroxide.

[0139] Preferably, the cosmetic composition comprises one or more basifying agents chosen from alkanolamines, in particular triethanolamine, and sodium hydroxide.

[0140] Mention may be made, among the active agents for caring for keratin materials, such as the skin, the lips, the scalp, the hair, the eyelashes or the nails, of, for example, vitamins and their derivatives or precursors, alone or as mixtures; antioxidants; agents for combating free radicals; agents for combating pollutants; self-tanning agents; antiglycation agents; soothing agents; deodorant agents; essential oils; NO- synthase inhibitors; agents which stimulate the synthesis of dermal or epidermal macromolecules and/or which prevent their decomposition; agents which stimulate the proliferation of fibroblasts; agents which stimulate the proliferation of keratinocytes; muscle relaxants; refreshing agents; tightening agents; matifying agents; depigmenting agents; propigmenting agents; keratolytic agents; desquamating agents; moisturizing agents; anti-inflammatory agents; antimicrobial agents; slimming agents; agents which act on the energy metabolism of the cells; insect repellents; substance P or CRGP antagonists; agents for combating hair loss; antiwrinkle agents; anti-ageing agents. [0141 ] A person skilled in the art will choose said active agent(s) as a function of the effect desired on the skin, the hair, the eyelashes, the eyebrows or the nails.

[0142] Of course, a person skilled in the art will take care to choose the abovementioned optional additional compound(s) and/or their amounts so that the advantageous properties intrinsically attached to the compositions in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition(s).

PRESENTATION FORMS

[0143] The compositions in accordance with the invention can be aqueous or anhydrous.

[0144] When the compositions are aqueous, they contain at least one aqueous phase.

[0145] They can then be provided in a purely aqueous form, that is to say that they comprise an amount of fatty phase of less than 10% by weight, preferably of less than 5% by weight and more preferentially still of less than 2% by weight, with respect to the total weight of the composition. Advantageously, the composition in accordance with the invention is essentially aqueous, that is to say that it is devoid of fatty phase.

[0146] The compositions according to the invention can also be provided in the form of a simple or complex (O/W, W/O, O/W/O orW/O/W) emulsion, such as a cream, a milk or a gel-cream.

[0147] In the case where the composition in accordance with the invention is aqueous and it is possible to measure its pH, the latter is generally of between 3 and 12 approximately, preferably between 5 and 9 approximately and more particularly still from 5.5 to 8.

[0148] The compositions can also be provided in the anhydrous form, such as, for example, in the form of an oil, of an alcoholic solution or of a glycolic solution. The term "anhydrous composition" is understood to mean a composition containing less than 1 % by weight of water, indeed even less than 0.5% of water, and in particular devoid of water, the water not being added during the preparation of the composition but corresponding to the residual water contributed by the mixed ingredients. They can optionally be packaged as an aerosol and be provided in the form of a foam or of a spray.

[0149] In the case of compositions in the form of oil-in-water or water-in- oil emulsions, the emulsification processes which can be used are of the paddle or propeller, rotor-stator and HPH type.

[0150] In order to obtain stable emulsions with a low content of polymer (oil/polymer ratio > 25), it is possible to prepare the dispersion in concentrated phase and then to dilute the dispersion with the remainder of the aqueous phase.

[0151 ] It is also possible, via HPH (between 50 and 800 bar), to obtain stable dispersions with drop sizes that can be as small as 100 nm.

[0152] The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or as a mixture. The emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W).

[0153] Mention may be made, as examples of W/O emulsifying surfactants, of alkyl esters or ethers of sorbitan, of glycerol, of polyol or of sugars; or silicone surfactants, such as dimethicone copolyols, for example the mixture of cyclomethicone and dimethicone copolyol sold under the name DC 5225 C® by Dow Coming, and alkyl dimethicone copolyols, such as lauryl methicone copolyol, sold under the name Dow Coming 5200 Formulation Aid by Dow Coming, or cetyl dimethicone copolyol, such as the product sold under the name Abil EM 90R® by Goldschmidt and the mixture of cetyl dimethicone copolyol, polyglyceryl isostearate (4 mol) and hexyl laurate sold under the name Abil WE 09® by Goldschmidt. It is also possible to add thereto one or more coemulsifiers which, advantageously, can be chosen from the group consisting of polyol alkyl esters.

[0154] Mention may also be made of non-silicone emulsifying surfactants, in particular alkyl esters or ethers of sorbitan, of glycerol, of polyol or of sugars.

[0155] Mention may in particular be made, as polyol alkyl esters, of polyethylene glycol esters, such as PEG-30 Dipolyhydroxystearate, such as the product sold under the name Arlacel P135® by ICI.

[0156] Mention may be made, as glycerol and/or sorbitan esters, for example, of polyglyceryl isostearate, such as the product sold under the name Isolan Gl 34® by Goldschmidt; sorbitan isostearate, such as the product sold under the name Arlacel 987® by ICI; sorbitan glyceryl isostearate, such as the product sold under the name Arlacel 986® by ICI, and their mixtures.

[0157] Mention may be made, for the O/W emulsions, for example, as non-ionic emulsifying surfactants, of polyoxyalkylenated (more particularly polyoxyethylenated and/or polyoxypropylenated) esters of fatty acids and of glycerol; oxyalkylenated esters of fatty acids and of sorbitan; polyoxyalkylenated (in particular polyoxyethylenated and/or polyoxypropylenated) esters of fatty acids, optionally in combination with an ester of a fatty acid and of glycerol, such as the PEG-100 Stearate/Glyceryl Stearate mixture sold, for example, by ICI under the name Arlacel 165; oxyalkylenated (oxyethylenated and/or oxypropylenated) ethers of fatty alcohols; esters of sugars, such as sucrose stearate; or ethers of fatty alcohol and of sugar, in particular alkyl polyglucosides (APGs), such as decyl glucoside and lauryl glucoside, sold, for example, by Henkel under the respective names Plantaren 2000® and Plantaren 1200®, cetostearyl glucoside, optionally as a mixture with cetostearyl alcohol, sold, for example, under the name Montanov 68® by SEPPIC, under the name Tegocare CG90® by Goldschmidt and under the name Emulgade KE3302® by Henkel, and arachidyl glucoside, for example in the form of the mixture of arachidyl and behenyl alcohols and of arachidyl glucoside sold under the name Montanov 202® by SEPPIC. According to a specific embodiment of the invention, the mixture of the alkyl polyglucoside as defined above with the corresponding fatty alcohol can be in the form of a self-emulsifying composition, as described, for example, in the document WO-A-92/06778. [0158] When it is an emulsion, the aqueous phase of the latter can comprise a non-ionic vesicular dispersion prepared according to known processes (Bangham, Standish and Watkins, J. Mol. Biol., 13, 238 (1965), FR 2 315 991 and FR 2 416 008).

[0159] The compositions according to the invention have applications in a large number of treatments, in particular cosmetic treatments, of the skin, lips and hair, including the scalp, in particular for protecting and/or caring for the skin, lips and/or hair and/or for making up the skin and/or lips.

[0160] Another subject-matter of the present invention is constituted of the use of the compositions according to the invention as defined above in the manufacture of products for the cosmetic treatment of the skin, lips, nails, hair, eyelashes, eyebrows and/or scalp, in particular of care products, sun protection products and make-up products.

[0161 ] The cosmetic compositions according to the invention can be used, for example, as make-up products.

[0162] Another subject-matter of the present invention is constituted of a non-therapeutic cosmetic method for caring for and/or making up a keratin material, which consists in applying, to the surface of said keratin material, at least one composition according to the invention as defined above.

[0163] Another subject-matter of the invention is constituted of the use of resveratrol and/or of one of its derivatives to dissolve a merocyanine of formula (3) as defined above.

[0164] According to a specific embodiment, the resveratrol and/or one of its derivatives makes it possible to dissolve the merocyanines in accordance with the invention in the fatty phase and/or in the aqueous phase.

[0165] The cosmetic compositions according to the invention can, for example, be used as care products and/or sun protection products for the face and/or body with a liquid to semi-liquid consistency, such as milks, more or less smooth creams, gel-creams or pastes. They can optionally be packaged as an aerosol and be provided in the form of a foam or of a spray. [0166] The compositions according to the invention in the form of vaporizable fluid lotions in accordance with the invention are applied to the skin or the hair in the form of fine particles by means of pressurization devices. The devices in accordance with the invention are well known to a person skilled in the art and comprise non-aerosol pumps or "atomizers", aerosol containers comprising a propellant and aerosol pumps using compressed air as propellant. These devices are described in Patents US 4 077 441 and US 4 850 517.

[0167] The compositions packaged as an aerosol in accordance with the invention generally contain conventional propellants, such as, for example, hydrofluorinated compounds, dichlorodifluoromethane, difluoroethane, dimethyl ether, isobutane, n-butane, propane or trichlorofluoromethane. They are preferably present in amounts ranging from 15% to 50% by weight, with respect to the total weight of the composition.

ASSEMBLY

[0168] According to another aspect, the invention also relates to a cosmetic assembly comprising: i) a container delimiting one or more compartment(s), said container being closed by a closing member and optionally being unsealed; and ii) a make-up and/or care composition in accordance with the invention placed inside said compartment(s).

[0169] The container can, for example, be in the form of a pot or a case.

[0170] The closing member can be in the form of a lid comprising a cap mounted so as to be able to move by translation or by pivoting relative to the container housing said make-up and/or care composition(s).

EXAMPLES

[0171 ] The examples which follow serve to illustrate the invention without, however, exhibiting a limiting nature. [0172] Example A1 : Preparation of the compound (14)

[Formula 14]

[0173] 122.23 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1- one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 75.45 grams of ethyl cyanoacetate in approximately equimolar proportions in the presence of a base and optionally of a solvent.

[0174] The base/solvent combinations indicated in the following table are used.

[Table 2]

[0175] The completion of the alkylation reaction can be monitored, for example by methods such as TLC, GC or HPLC.

[0176] 162.30 grams of compound (14) are obtained in the form of a brown oil.

[0177] After crystallization, the product is obtained in the form of yellowish crystals.

[0178] Melting point: 92.7°C.

[0179] Example A2: Preparation of the compound (15)

SUBSTITUTE SHEET (RULE 26)

[0180] 101.00 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1- one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 86.00 grams of 2-cyano-N-(3-methoxypropyl)acetamide in approximately equimolar proportions in the presence of a base and optionally of a solvent.

[0181 ] The base/solvent combinations indicated in the following table are used. [Table 3]

[0182] The crude product (15) is obtained in the form of a dark brown oil.

[0183] After silica gel column chromatography (eluent: 99/1 toluene/methanol), 81.8 grams of product are obtained in the form of yellowish crystals.

[0184] Melting point: 84.7-85.3°C.

[0185] Example A3: Preparation of the compound (27)

SUBSTITUTE SHEET (RULE 26) [Formula 27]

[0186] 13.09 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 10.12 grams of isobutyl cyanoacetate in the presence of a base and optionally of a solvent.

[0187] The base/solvent combinations indicated in the following table are used.

[Table 4]

[0188] 15.97 grams of crude product (27) are obtained in the form of a dark brown oil.

[0189] After silica gel column chromatography (eluent: toluene/acetone), 13.46 grams of product are obtained in the form of yellowish crystals. [0190] Melting point: 96.3°C.

[0191] Example A4: Preparation of the compound (25)

[Formula 25]

SUBSTITUTE SHEET (RULE 26) [0192] 148.4 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 130.00 grams of 2-ethoxyethyl cyanoacetate in the presence of an organic base and of a solvent.

[0193] The base/solvent combinations indicated in the table below are used.

[Table 5]

[0194] Formulation examples

[0195] Examples 1 to 4: Study of the solubility of the compound 25

[0196] In these examples, the amounts of the ingredients in the compositions are given as % by weight of starting materials, with respect to the total weight of the composition.

[0197] Protocol for evaluation of the solubility

[0198] The solubility of the merocyanine within the oily and/or aqueous solutions can be evaluated macroscopically and/or microscopically. It is considered that the merocyanine is soluble if, at ambient temperature, the solution appears clear and translucent to the naked eye and it does not exhibit crystals visible under a microscope in white or polarized light (objective x20 to x40).

[0199] In the examples which follow, the solubility is evaluated macroscopically. It is evaluated at ambient temperature, on the day of the preparation of the solution and then over time. During this period of time, the solutions are stored at ambient temperature.

SUBSTITUTE SHEET (RULE 26) [0200] Examples 1 and 2: Dissolution in the presence of resveratrol

[0201] The following solutions were prepared according to the process below.

[Table 6]

[0202] ' Examples 3 and 4: Dissolution in the presence of polydatin

[0203] The following solutions were prepared according to the process below.

[Table 7]

SUBSTITUTE SHEET (RULE 26)

[0204] Mode of preparation of the compositions of 1 to 4:

[0205] The compositions described in Examples 1 to 4 are prepared in the following way: the different starting materials are introduced successively into a container before being mixed by means of a magnetic stirrer and being heated from 80 to 90°C for 1 hour, until all the compounds (merocyanine and resveratrol derivatives) have dissolved.

[0206] The mixtures are subsequently left standing in order to return to ambient temperature, in which they are stored. [0207] Results:

[0208] The results obtained show that resveratrol and the resveratrol derivatives according to the invention make it possible to maintain the solubility of merocyanine for a longer time.

[0209] Examples 5 and 6: Dissolution in the presence of resveratrol triphosphate

[0210] The following solutions were prepared according to the process below. In these examples, the amounts of the ingredients in the compositions are given as amount in g of starting materials introduced into the composition.

[Table 8]

SUBSTITUTE SHEET (RULE 26)

[0211 ] Procedure and protocol for evaluation of the solubility:

[0212] All the ingredients are mixed and left under mechanical stirring for 24 hours at ambient temperature. [0213] The mixture is filtered by virtue of a PTFE syringe filter with a diameter of 0.2 pm in order to extract a clear liquid.

[0214] 30 pl of the liquid are withdrawn and diluted in 5 ml of ethanol.

[0215] The diluted solution is introduced into a 1 cm cell and a UV/visible spectrum of the solution is recorded. [0216] Apparatus: Perkin Elmer Lambda 19 spectrophotometer.

[0217] Results:

[0218] The results obtained show that the resveratrol derivative according to the invention makes it possible to dissolve a greater amount of merocyanine in water.

SUBSTITUTE SHEET (RULE 26)